TY - JOUR
T1 - Recommendations for treating children with drug-resistant tuberculosis
AU - Galli, Luisa
AU - Lancella, Laura
AU - Garazzino, Silvia
AU - Tadolini, Marina
AU - Matteelli, Alberto
AU - Migliori, Giovanni Battista
AU - Principi, Nicola
AU - Villani, Alberto
AU - Esposito, Susanna
AU - Tortoli, Enrico
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Tuberculosis (TB) is still one of the most difficult infectious diseases to treat, and the second most frequent cause of death due to infectious disease throughout the world. The number of cases of multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB), which are characterised by high mortality rates, is increasing. The therapeutic management of children with MDR- and XDR-TB is complicated by a lack of knowledge, and the fact that many potentially useful drugs are not registered for pediatric use and there are no formulations suitable for children in the first years of life. Furthermore, most of the available drugs are burdened by major adverse events that need to be taken into account, particularly in the case of prolonged therapy. This document describes the recommendations of a group of scientific societies on the therapeutic approach to pediatric MDR- and XDR-TB. On the basis of a systematic literature review and their personal clinical experience, the experts recommend that children with active TB caused by a drug-resistant strain of Mycobacterium tuberculosis should always be referred to a specialised centre because of the complexity of patient management, the paucity of pediatric data, and the high incidence of adverse events due to second-line anti-TB treatment.
AB - Tuberculosis (TB) is still one of the most difficult infectious diseases to treat, and the second most frequent cause of death due to infectious disease throughout the world. The number of cases of multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB), which are characterised by high mortality rates, is increasing. The therapeutic management of children with MDR- and XDR-TB is complicated by a lack of knowledge, and the fact that many potentially useful drugs are not registered for pediatric use and there are no formulations suitable for children in the first years of life. Furthermore, most of the available drugs are burdened by major adverse events that need to be taken into account, particularly in the case of prolonged therapy. This document describes the recommendations of a group of scientific societies on the therapeutic approach to pediatric MDR- and XDR-TB. On the basis of a systematic literature review and their personal clinical experience, the experts recommend that children with active TB caused by a drug-resistant strain of Mycobacterium tuberculosis should always be referred to a specialised centre because of the complexity of patient management, the paucity of pediatric data, and the high incidence of adverse events due to second-line anti-TB treatment.
KW - Anti-tuberculosis drugs
KW - Children
KW - MDR-TB
KW - Pediatric tuberculosis
KW - XDR-TB
UR - http://www.scopus.com/inward/record.url?scp=84956964941&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84956964941&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2016.01.020
DO - 10.1016/j.phrs.2016.01.020
M3 - Review article
VL - 105
SP - 176
EP - 182
JO - Pharmacological Research
JF - Pharmacological Research
SN - 1043-6618
ER -